NCT04873323

A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects

A Study to Evaluate the Effects on QT/QTc Interval of TS-142 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Taisho Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 39 Years
• Healthy volunteers: Accepted

Summary

A clinical study to evaluate the effects on QT/QTc Interval of TS-142 in Healthy Adult Subjects

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	TS-142	Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period
DRUG	Moxifloxacin	Single dose of moxifloxacin 400 mg in the morning under fasting in each period
DRUG	Placebo	Single dose of TS-142 placebo in the morning under fasting in each period

Timeline

• Start date: 2021-06-07
• Primary completion: 2021-09-28
• Completion: 2021-09-28
• First posted: 2021-05-05
• Last updated: 2025-02-28

Locations

1 site across 1 country: Japan